Macropore Inc. IR-Pages
MacroPore Biosurgery Appoints Chief Financial Officer
Ad-hoc-announcement processed and transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MacroPore Biosurgery Appoints Chief Financial Officer;
Announces Management Promotions
San Diego, CA, June 23, 2004 – MacroPore Biosurgery, Inc. (Frankfurt: XMP)
(Reuters: MACP.DE) (XMP:GR) today announced the appointment of Mark E. Saad to
the Position of Chief Financial Officer and the promotions of Marc H. Hedrick,
M.D., to President and Sharon V. Schulzki to Chief Operating Officer.
Mr. Saad joins MacroPore Biosurgery from UBS Investment Bank where he worked
from 1999 to 2004 and most recently served as the Chief Operating Officer of the
Global Healthcare Group. At MacroPore Biosurgery, he will be responsible for
all financial functions, corporate development, and investor relations.
Previously he worked with Salomon Smith Barney in their Healthcare Investment
Banking Group from 1993 to 1999.
“We look forward to benefiting from Mark’s extensive experience within the
biotechnology and medical device industries, where he recently helped build the
largest international healthcare banking team,” said Christopher J. Calhoun,
Chief Executive Officer of MacroPore Biosurgery. “He joins us at an important
time, as we move closer to a dual-listing in the United States and begin to more
aggressively pursue partnering opportunities for our regenerative cell
technology program.”
“Over the past three years, we have assembled an extremely dynamic and
accomplished management team that will be very instrumental to our continued
growth,” added Mr. Calhoun. “The promotions of Marc and Sharon are in part to
acknowledge their key contributions to the Company to date and, more
importantly, to further position the company for success in regenerative
medicine.”
end of ad-hoc-announcement (c)DGAP 23.06.2004
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) is focused on the discovery, development
and commercialization of regenerative medicine technologies. We have two
technology platforms, bioresorbable technology and regenerative cell technology.
Our surgical implants, derived from our bioresorbable technology, represent one
of the latest advancements in spine and orthopedic medicine. They are
manufactured by us and distributed exclusively through Medtronic Sofamor Danek.
Within our regenerative cell technology program, we are developing a system to
isolate autologous, homologous-use, regenerative cells. Simultaneously, we are
generating scientific knowledge through internal research to support the
clinical use of these cells. Our most advanced research and development program
is in the repair of cardiovascular tissues that are damaged after a heart
attack. We are also researching applications in bone repair, spinal disc
regeneration, and cosmetic and reconstructive surgery. For further information
please visit our web site http://www.macropore.com .
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2003 Form 10-K annual report for the year ended
December 31, 2003, which is available on our web site. MacroPore Biosurgery
assumes no responsibility to publicly release the results of any revision of
forward-looking statements to reflect events, trends or circumstances after the
date they are made.
Contacts:
Tom Baker Stefanie Bacher
Media/U.S.-Investors European Investors
Tel. +1-858-458-0900 Tel. +1-858-362-0365
tbaker@macropore.com sbacher@macropore.com
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
231701 Jun 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found